4.4 Article

Type 1 papillary renal cell carcinoma in a patient with schwannomatosis: Mosaic versus loss of SMARCBI expression in respectively schwannoma and renal tumor cells

期刊

GENES CHROMOSOMES & CANCER
卷 55, 期 4, 页码 350-354

出版社

WILEY-BLACKWELL
DOI: 10.1002/gcc.22338

关键词

-

向作者/读者索取更多资源

In schwannomatosis, germline SMARCB1 or LZTR1 mutations predispose to the development of multiple benign schwannomas. Besides these, other tumors may occur in schwannomatosis patients. We present a 45-year-old male patient who developed multiple schwannomas and in addition a malignant type 1 papillary renal cell carcinoma (pRCC1). We identified a duplication of exon 7 of SMARCB1 on chromosome 22 in the constitutional DNA of the patient (c.796-2246_986+5250dup7686), resulting in the generation of a premature stop codon in the second exon 7 copy (p.Glu330*). The mutant SMARCB1 allele proved to be retained in three schwannomas and in the pRCC1 of the patient. Loss of heterozygosity analysis demonstrated partial loss of the wild-type SMARCB1 allele containing chromosome 22, suggesting loss of that chromosome in only a subset of tumor cells, in all four tumors. Immunohistochemical staining with a SMARCB1 antibody revealed a mosaic SMARCB1 expression pattern in the three benign schwannomas, but absence of expression in the malignant tumor cells of the pRCC1. To our knowledge, this difference in SMARCB1 protein expression has not been reported before. We conclude that a germline SMARCB1 mutation may predispose to the development of pRCC1, thereby further widening the spectrum of tumors that can develop in the context of schwannomatosis. (c) 2016 Wiley Periodicals, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Clinical Neurology

Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia

Alberto Benussi, Antonella Alberici, Kiran Samra, Lucy L. Russell, Caroline Greaves, Martina Bocchetta, Simon Ducharme, Elizabeth Finger, Giorgio Fumagalli, Daniela Galimberti, Lize C. Jiskoot, Isabelle Le Ber, Mario Masellis, Benedetta Nacmias, James B. Rowe, Raquel Sanchez-Valle, Harro Seelaar, Matthis Synofzik, Jonathan D. Rohrer, Barbara Borroni

Summary: The presymptomatic stages of frontotemporal dementia (FTD) have not been clearly defined, indicating a need for a consensus lexicon to comprehensively describe the stages that anticipate dementia and to formulate a better strategy for characterizing these disease stages.

ALZHEIMERS & DEMENTIA (2022)

Article Clinical Neurology

Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum NfL and pNfH: A Longitudinal Multicentre Study

Carlo Wilke, Selina Reich, John C. van Swieten, Barbara Borroni, Raquel Sanchez-Valle, Fermin Moreno, Robert Laforce, Caroline Graff, Daniela Galimberti, James B. Rowe, Mario Masellis, Maria C. Tartaglia, Elizabeth Finger, Rik Vandenberghe, Alexandre de Mendonca, Fabrizio Tagliavini, Isabel Santana, Simon Ducharme, Chris R. Butler, Alexander Gerhard, Johannes Levin, Adrian Danek, Markus Otto, Giovanni Frisoni, Roberta Ghidoni, Sandro Sorbi, Martina Bocchetta, Emily Todd, Jens Kuhle, Christian Barro, Jonathan D. Rohrer, Matthis Synofzik

Summary: This study provides a biomarker cascade for the conversion stage in presymptomatic frontotemporal dementia, using serum neurofilament levels to stratify individuals in different stages and potentially identify those converting to symptomatic disease. The biomarker cascade may pave the way towards a biomarker-based precision medicine approach to genetic FTD.

ANNALS OF NEUROLOGY (2022)

Article Clinical Neurology

A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia

Emma L. van der Ende, Esther E. Bron, Jackie M. Poos, Lize C. Jiskoot, Jessica L. Panman, Janne M. Papma, Lieke H. Meeter, Elise G. P. Dopper, Carlo Wilke, Matthis Synofzik, Carolin Heller, Imogen J. Swift, Aitana Sogorb-Esteve, Arabella Bouzigues, Barbara Borroni, Raquel Sanchez-Valle, Fermin Moreno, Caroline Graff, Robert Laforce, Daniela Galimberti, Mario Masellis, Maria Carmela Tartaglia, Elizabeth Finger, Rik Vandenberghe, James B. Rowe, Alexandre de Mendonca, Fabrizio Tagliavini, Isabel Santana, Simon Ducharme, Christopher R. Butler, Alexander Gerhard, Johannes Levin, Adrian Danek, Markus Otto, Yolande A. L. Pijnenburg, Sandro Sorbi, Henrik Zetterberg, Wiro J. Niessen, Jonathan D. Rohrer, Stefan Klein, John C. van Swieten, Vikram Venkatraghavan, Harro Seelaar

Summary: This study aimed to model the sequence of biomarker abnormalities in genetic frontotemporal dementia and determine the disease stages of patients. The results showed that NPTX2 and neurofilament light chain were the earliest biomarkers to change. This model could help select suitable patients for pharmaceutical trials and improve patient stratification and tracking of therapeutic interventions.
Article Behavioral Sciences

Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort

Phoebe H. Foster, Lucy L. Russell, Georgia Peakman, Rhian S. Convery, Arabella Bouzigues, Caroline Greaves, Martina Bocchetta, David M. Cash, John C. van Swieten, Lize C. Jiskoot, Fermin Moreno, Raquel Sanchez-Valle, Robert Laforce, Caroline Graff, Mario Masellis, Carmela Tartaglia, James B. Rowe, Barbara Borroni, Elizabeth Finger, Matthis Synofzik, Daniela Galimberti, Rik Vandenberghe, Alexandre de Mendonca, Chris R. Butler, Alex Gerhard, Simon Ducharme, Isabelle Le Ber, Fabrizio Tagliavini, Isabel Santana, Florence Pasquier, Johannes Levin, Adrian Danek, Markus Otto, Sandro Sorbi, Jonathan D. Rohrer

Summary: Significant empathy deficits are present in genetic frontotemporal dementia (FTD). Individuals with symptomatic and behavioral variant FTD phenotype, as well as C9orf72 expansion carriers, score lower on empathy assessments.

CORTEX (2022)

Article Neurosciences

Data-driven staging of genetic frontotemporal dementia using multi-modal MRI

Jillian McCarthy, Barbara Borroni, Raquel Sanchez-Valle, Fermin Moreno, Robert Laforce, Caroline Graff, Matthis Synofzik, Daniela Galimberti, James B. Rowe, Mario Masellis, Maria Carmela Tartaglia, Elizabeth Finger, Rik Vandenberghe, Alexandre de Mendonca, Fabrizio Tagliavini, Isabel Santana, Chris Butler, Alex Gerhard, Adrian Danek, Johannes Levin, Markus Otto, Giovanni Frisoni, Roberta Ghidoni, Sandro Sorbi, Lize C. Jiskoot, Harro Seelaar, John C. van Swieten, Jonathan D. Rohrer, Yasser Iturria-Medina, Simon Ducharme

Summary: Frontotemporal dementia in genetic forms is highly heterogeneous and begins many years prior to symptom onset. This study used an unsupervised machine learning algorithm, cTI, to analyze large-scale population datasets and obtained individual scores of disease stage based on MRI metrics. The results suggest that cTI can identify data-driven disease stages in genetic forms of frontotemporal dementia.

HUMAN BRAIN MAPPING (2022)

Article Clinical Neurology

Cognitive composites for genetic frontotemporal dementia: GENFI-Cog

Jackie M. Poos, Katrina M. Moore, Jennifer Nicholas, Lucy L. Russell, Georgia Peakman, Rhian S. Convery, Lize C. Jiskoot, Emma van der Ende, Esther van den Berg, Janne M. Papma, Harro Seelaar, Yolande A. L. Pijnenburg, Fermin Moreno, Raquel Sanchez-Valle, Barbara Borroni, Robert Laforce, Mario Masellis, Carmela Tartaglia, Caroline Graff, Daniela Galimberti, James B. Rowe, Elizabeth Finger, Matthis Synofzik, Rik Vandenberghe, Alexandre de Mendonca, Pietro Tiraboschi, Isabel Santana, Simon Ducharme, Chris Butler, Alexander Gerhard, Johannes Levin, Adrian Danek, Markus Otto, Isabel Le Ber, Florence Pasquier, John C. van Swieten, Jonathan D. Rohrer

Summary: This study created cognitive composite scores for genetic frontotemporal dementia (FTD) and provided recommendations for recruitment and duration in clinical trial design.

ALZHEIMERS RESEARCH & THERAPY (2022)

Article Geriatrics & Gerontology

Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia

Stefano Gazzina, Mario Grassi, Enrico Premi, Antonella Alberici, Alberto Benussi, Silvana Archetti, Roberto Gasparotti, Martina Bocchetta, David M. Cash, Emily G. Todd, Georgia Peakman, Rhian S. Convery, John C. van Swieten, Lize C. Jiskoot, Harro Seelaar, Raquel Sanchez-Valle, Fermin Moreno, Robert Laforce, Caroline Graff, Matthis Synofzik, Daniela Galimberti, James B. Rowe, Mario Masellis, Maria Carmela Tartaglia, Elizabeth Finger, Rik Vandenberghe, Alexandre de Mendonca, Fabrizio Tagliavini, Chris R. Butler, Isabel Santana, Alexander Gerhard, Isabelle Le Ber, Florence Pasquier, Simon Ducharme, Johannes Levin, Adrian Danek, Sandro Sorbi, Markus Otto, Jonathan D. Rohrer, Barbara Borroni

Summary: This study investigated the relationship between GRN mutations and frontotemporal dementia and applied graph theory to analyze cortical thickness data. The results showed that global connectivity was significantly impaired in symptomatic GRN mutation carriers, while local connectivity exhibited perturbation only in carriers with symptoms.

NEUROBIOLOGY OF AGING (2022)

Article Clinical Neurology

The CBI-R detects early behavioural impairment in genetic frontotemporal dementia

Annabel Nelson, Lucy L. Russell, Georgia Peakman, Rhian S. Convery, Arabella Bouzigues, Caroline Greaves, Martina Bocchetta, David M. Cash, John C. Swieten, Lize Jiskoot, Fermin Moreno, Raquel Sanchez-Valle, Robert Laforce, Caroline Graff, Mario Masellis, Maria Carmela Tartaglia, James B. Rowe, Barbara Borroni, Elizabeth Finger, Matthis Synofzik, Daniela Galimberti, Rik Vandenberghe, Alexandre Mendonca, Chris R. Butler, Alexander Gerhard, Simon Ducharme, Isabelle Le Ber, Isabel Santana, Florence Pasquier, Johannes Levin, Markus Otto, Sandro Sorbi, Jonathan D. Rohrer

Summary: This study assessed behavioral changes in genetic frontotemporal dementia (FTD) using the revised version of the Cambridge Behavioral Inventory (CBI-R). The CBI-R was found to be effective in detecting early behavioral changes in FTD. Differences in behavior were observed among different genetic groups, particularly in domains related to motivation, stereotypic and motor behaviors, and memory and orientation. There were overlapping neural correlates of each CBI-R domain among the different mutation carrier groups.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2022)

Article Clinical Neurology

Effect of NOTCH3 EGFr Group, Sex, and Cardiovascular Risk Factors on CADASIL Clinical and Neuroimaging Outcomes

Remco J. Hack, Minne N. Cerfontaine, Gido Gravesteijn, Stephan Tap, Anne Hafkemeijer, Jeroen van der Grond, Marie-Noelle Witjes-Ane, Frank Baas, Julie W. Rutten, Saskia A. J. Lesnik Oberstein

Summary: This study is the first genotype-driven, large prospective CADASIL cohort study, and the results indicate that the NOTCH3 EGFr group is the most important modifier in CADASIL disease. Male sex and hypertension also have a significant impact on clinical outcomes and neuroimaging markers.

STROKE (2022)

Article Genetics & Heredity

High-yield identification of pathogenic NF1 variants by skin fibroblast transcriptome screening after apparently normal diagnostic DNA testing

Hannie C. W. Douben, Mark Nellist, Leontine van Unen, Peter Elfferich, Esmee Kasteleijn, Marianne Hoogeveen-Westerveld, Jesse Louwen, Monique Van Veghel-Plandsoen, Walter de Valk, Jasper J. Saris, Femke Hendriks, Esther Korpershoek, Lies H. Hoefsloot, Margreethe van Vliet, Yolande van Bever, Ingrid van de Laar, Emmelien Aten, Augusta M. A. Lachmeijer, Walter Taal, Lisa van den Bersselaar, Juliette Schuurmans, Rianne Oostenbrink, Rick van Minkelen, Yvette van Ierland, Tjakko J. van Ham

Summary: Neurofibromatosis type 1 (NF1) is caused by inactivating mutations in NF1. Transcriptome analysis on RNA obtained from cultured skin fibroblasts can help identify disease-causing variants in individuals with NF1 who were not identified by routine DNA diagnostics. This approach improves mutation detection in NF1 and can be applied to other genetic disorders.

HUMAN MUTATION (2022)

Article Biochemistry & Molecular Biology

Therapeutic Intervention with Anti-Complement Component 5 Antibody Does Not Reduce NASH but Does Attenuate Atherosclerosis and MIF Concentrations in Ldlr-/-.Leiden Mice

Florine Seidel, Robert Kleemann, Wim van Duyvenvoorde, Nikki van Trigt, Nanda Keijzer, Sandra van der Kooij, Cees van Kooten, Lars Verschuren, Aswin Menke, Amanda J. Kiliaan, Johnathan Winter, Timothy R. Hughes, B. Paul Morgan, Frank Baas, Kees Fluiter, Martine C. Morrison

Summary: Complement inhibition with an anti-C5 antibody is not effective in reducing the progression of NASH but is beneficial in established atherosclerosis.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Article Immunology

Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study

Emma L. van der Ende, Carolin Heller, Aitana Sogorb-Esteve, Imogen J. Swift, David McFall, Georgia Peakman, Arabella Bouzigues, Jackie M. Poos, Lize C. Jiskoot, Jessica L. Panman, Janne M. Papma, Lieke H. Meeter, Elise G. P. Dopper, Martina Bocchetta, Emily Todd, David Cash, Caroline Graff, Matthis Synofzik, Fermin Moreno, Elizabeth Finger, Raquel Sanchez-Valle, Rik Vandenberghe, Robert Laforce, Mario Masellis, Maria Carmela Tartaglia, James B. Rowe, Chris Butler, Simon Ducharme, Alexander Gerhard, Adrian Danek, Johannes Levin, Yolande A. L. Pijnenburg, Markus Otto, Barbara Borroni, Fabrizio Tagliavini, Alexandre de Mendonca, Isabel Santana, Daniela Galimberti, Sandro Sorbi, Henrik Zetterberg, Eric Huang, John C. van Swieten, Jonathan D. Rohrer, Harro Seelaar

Summary: This study explores the value of complement proteins as biomarkers in cerebrospinal fluid (CSF) and plasma of presymptomatic and symptomatic genetic frontotemporal dementia (FTD) mutation carriers. The results indicate elevated levels of certain complement proteins in symptomatic carriers, and correlations between complement protein levels and disease measures in presymptomatic carriers. Further research is needed to determine the potential of these proteins in monitoring complement system dysregulation in FTD.

JOURNAL OF NEUROINFLAMMATION (2022)

Letter Neurosciences

Letter to the editor on a paper by Kaivola et al. (2020): carriership of two copies of C9orf72 hexanucleotide repeat intermediate-length alleles is not associated with amyotrophic lateral sclerosis or frontotemporal dementia

Sterre C. M. de Boer, Lauren Woolley, Merel O. Mol, Maria Serpente, Lianne M. Reus, Rick van Minkelen, Joke F. A. van Vugt, Federica Sorrentino, Jan H. Veldink, Harro Seelaar, Daniela Galimberti, Fred van Ruissen, Simon Mead, Ekaterina Rogaeva, Yolande A. L. Pijnenburg, Sven J. van der Lee

ACTA NEUROPATHOLOGICA COMMUNICATIONS (2022)

Editorial Material Oncology

ASO Visual Abstract: Predicting Lymph Node Metastases in Patients with Biopsy-Proven Ductal Carcinoma In Situ of the Breast: Development and Validation of the DCIS-met Model

Claudia J. C. Meurs, Joost van Rosmalen, Marian B. E. Menke-Pluijmers, Sabine Siesling, Pieter J. J. Westenend

ANNALS OF SURGICAL ONCOLOGY (2023)

Article Clinical Neurology

Hierarchical spectral clustering reveals brain size and shape changes in asymptomatic carriers of C9orf72

Rose Bruffaerts, Dorothy Gors, Alicia Barcenas Gallardo, Mathieu Vandenbulcke, Philip Van Damme, Paul Suetens, John C. van Swieten, Barbara Borroni, Raquel Sanchez-Valle, Fermin Moreno, Robert Laforce, Caroline Graff, Matthis Synofzik, Daniela Galimberti, James B. Rowe, Mario Masellis, Maria Carmela Tartaglia, Elizabeth Finger, Alexandre de Mendonca, Fabrizio Tagliavini, Chris R. Butler, Isabel Santana, Alexander Gerhard, Simon Ducharme, Johannes Levin, Adrian Danek, Markus Otto, Jonathan D. Rohrer, Patrick Dupont, Peter Claes, Rik Vandenberghe

Summary: This study explored structural brain changes in the asymptomatic stage of monogenic frontotemporal degeneration using hierarchical spectral clustering. The results demonstrated that this method could detect additional changes compared to conventional methods, providing a more comprehensive understanding of the disease progression.

BRAIN COMMUNICATIONS (2022)

暂无数据